Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evaluating drug effects on children's cognitive functioning.

H B Ferguson, J G Simeon

    Progress in Neuro-Psychopharmacology & Biological Psychiatry
    |January 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Community factors in the development of resiliency: considerations and future directions.

    Community mental health journal·2001
    Same author

    Sertraline effects in adolescent major depression and dysthymia: a six-month open trial.

    Journal of child and adolescent psychopharmacology·2001
    Same author

    Challenges to pediatric psychopharmacology.

    Journal of psychiatry & neuroscience : JPN·1997
    Same author

    World wide use of psychotropic drugs in child and adolescent psychiatric disorders.

    Progress in neuro-psychopharmacology & biological psychiatry·1995
    Same author

    Response to desipramine treatment in adolescent depression: a fixed-dose, placebo-controlled trial.

    Journal of the American Academy of Child and Adolescent Psychiatry·1994
    Same author

    Pharmacotherapy of attention-deficit hyperactivity disorder.

    Canadian journal of psychiatry. Revue canadienne de psychiatrie·1993
    Same journal

    Mapping intrinsic neural timescale alterations in major depressive disorder.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Probiotics in reducing negative symptoms of schizophrenia: A systematic review and meta-analysis.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    The IL10 rs1800872 polymorphism differentially modulates the relationship between plasma IL-10 levels and cognitive function in methamphetamine use disorder.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Inflammatory differences and differential response to minocycline augmentation in young adult patients with first-episode drug-naïve melancholic and non-melancholic major depressive disorder.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Beyond gray matter: unveiling the critical role of white matter in Alzheimer's disease.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Chronic pain and stress: Transdiagnostic meta-analytic evidence of convergent network signature with PTSD.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    See all related articles

    This study found that bupropion (Wellbutrin) and alprazolam (Xanax) did not negatively impact cognitive skills in children with psychiatric disorders. Cognitive testing showed no adverse effects at effective doses.

    Area of Science:

    • Child Psychiatry
    • Neuroscience
    • Pharmacology

    Background:

    • Assessing medication effects on cognitive processing is crucial in child psychiatry.
    • Cognitive skills are vital for academic success in children.

    Purpose of the Study:

    • To evaluate the impact of bupropion and alprazolam on cognitive functions in pediatric patients.
    • To determine if these medications cause adverse cognitive effects relevant to classroom performance.

    Main Methods:

    • Utilized a cognitive test battery to monitor cognitive processing.
    • Conducted open clinical trials with child psychiatry patients receiving bupropion or alprazolam.
    • Compared medication effects against placebo where applicable.

    Main Results:

    Related Experiment Videos

    • Bupropion showed no significant negative effects on individual cognitive tests compared to placebo.
    • Alprazolam group performance was variable, with no significant changes on individual tests.
    • No cognitive deterioration was observed with either medication at therapeutic doses.

    Conclusions:

    • Bupropion, an antidepressant, and alprazolam, an anxiolytic, appear safe for cognitive function in children at therapeutic doses.
    • The cognitive test battery is a useful tool for monitoring medication effects in pediatric psychopharmacology.